Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model.

ACS chemical neuroscience - 18 May 2016

Sourbron Jo, Schneider Henning, Kecskés Angéla, Liu Yusu, Buening Ellen M, Lagae Lieven, Smolders Ilse, de Witte Peter

Abstract excerpt

Dravet syndrome (DS) is a severe epilepsy syndrome that starts within the first year of life. In a clinical study, add-on treatment with fenfluramine, a potent 5-hydroxytryptamine (5-HT) releaser activating multiple 5-HT receptor subtypes, made 70% of DS children seizure free. Others and we recently confirmed the efficacy of fenfluramine as an antiepileptiform compound in zebrafish models of DS. By using a large...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epilepsies, Myoclonic

Share to Receptors, Serotonin

Share to Serotonin

Share to Serotonin Receptor Agonists

Share to Treatment Outcome

Share to Zebrafish

Source

Identifiers

PMID: 26822114
DOI: 10.1021/acschemneuro.5b00342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model.PMID 26822114Read ↗

Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafishSemantic proximity Read ↗

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluramineSemantic proximity Read ↗

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read ↗

Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndromeSemantic proximity Read ↗

Clemizole and Trazodone are Effective Antiseizure Treatments in a Zebrafish Model of STXBP1 DisorderSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read ↗

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndromeSemantic proximity Read ↗

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndromeSemantic proximity Read ↗

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

A 5-HT1D -receptor agonist protects Dravet syndrome mice from seizure and early death.Semantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet SyndromeSemantic proximity Read ↗

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.